Por: The New York Times Health May 19, 2023
An advisory panel to the Food and Drug Administration voted on Thursday in favor of approving a vaccine by Pfizer to prevent the severe respiratory virus that is a potentially deadly threat to infants.The vaccine would be the first to protect babies from respiratory syncytial virus, or R.S.V., which is the reason many infants are admitted to children’s hospitals each year and kills several hundred under 5 each year.Fourteen agency advisers... + full article
New York Post USA Life February 23, 2023
A vaccine to protect against severe cases of Respiratory Syncytial Virus could roll out as early as August. Pfizer has developed RSVpreF, a vaccine to prevent severe cases of RSV, and the Food and Drug Administration is reportedly expediting its review approval process. The FDA... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
CNBC USA Health February 22, 2023
David Paul Morris Bloomberg Getty Images's vaccine that protects infants from respiratory could receive Food and Drug Administration approval by the end of this summer.Pfizer on Tuesday said the FDA is reviewing the vaccine on an expedited basis. The agency is expected to... + más
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year | CNN
1st RSV vaccine could be approved this summer | ABC7
ABC7 USA Health February 21, 2023
A Pfizer logo is seen in this illustration, May 1, 2022.Dado Ruvic/Reuters, FILERSV usually causes mild, cold-like symptoms, but can become serious, especially for infants and older adults. Premature infants and young children with weakened immune systems, congenital heart or... + más
ABC7 USA World February 21, 2023
against , could be approved by August.Pfizer, the maker of the vaccine, that the U.S. Food and Drug Administration has accepted its application for review and will make a decision on whether or not to approve the vaccine by August 2023.If approved, RSVpreF would help protect... + más
CNBC USA Health November 11, 2022
Diane Macdonald Stockbyte Getty ImagesEven healthy infants face a considerable risk of hospitalization from respiratory syncytial virus, according to a large European study published Thursday.Dutch and British scientists, in a study published in Lancet Respiratory Medicine,... + más
Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7
Respiratory Therapist Adel Al Joaid treats Melissa Wartman, a COVID-19 patient, in the ICU at Rush University Medial Center on January 31, 2022 in Chicago, Illinois.Scott Olson Getty ImagesInfants too young for vaccination were hospitalized with Covid-19 more often than any age... + más
Nearly 2% of healthy infants hospitalized with RSV before first birthday, study finds | CNBC
FDA Approves GSK's Vaccine For Use In Pregnancy To Prevent Whooping Cough In Infants | RTTNews
RTTNews USA Health October 10, 2022
The FDA has approved GSK plc's () Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. The agency noted that Boostrix (Tetanus Toxoid, Reduced Diphtheria... + más
FDA clears vaccine to prevent whooping cough in newborns by giving shot to mother during pregnancy | CNBC
FDA warns against 'very unsafe' social media trends targeted at teenagers | ABC News
About iurex | Privacy Policy | Disclaimer |